

JDRF

FORWARD

TOGETHER AS 1

Table of Contents

Letter from the CEO	2
In Your Words	3
Curing T1D	5
Improving Lives	10
By the Numbers	17
Partners	24
Leadership Boards	25

Forward Together As 1

JDRF's vision is a world without type 1 diabetes (T1D). And in recent years, we've made incredible progress toward achieving that goal.

We've moved the standard of care for T1D from finger pokes to using CGMs, pumps, and artificial pancreas (AP) systems. We fought for access to these advancements and led the charge to get AP systems to the market.

These technologies are leading to healthier pregnancies, more time-in-range, fewer dangerous highs or lows, and even improved sleep.

We are thrilled that people with T1D are doing better. Now, it's time to look forward.

What do we see when we look forward?

We see that there has never been a more exciting time for our mission!

We see more people around the world with T1D living healthier lives because of life-changing breakthroughs we have championed.

We see new islet replacement therapies allowing people to take off their devices and walk away from T1D.

We see more disease-modifying therapies for T1D in the therapy development and access pipeline.

We see more affordable insulin: no more than \$30 a vial—regardless of insurance status for the equivalents of NovoLog®, Humalog®, and Lantus®—through our support of Civica Rx and advocacy efforts.

And we see millions more people around the world helping us accelerate cures and life-changing breakthroughs for all people with T1D.

On the following pages, you'll read about some of our most amazing advances today—where we are now, how we got here, and what more we see when we look forward.

All of this is only possible because of you—our steadfast supporters. You have always been the force moving us "Forward Together As 1." Because of you, cures are not a matter of if, but when.

Warm regards and many thanks,



Aaron J. Kowalski, Ph.D.
Chief Executive Officer, JDRF

In Your Words

You—our volunteers, advocates, donors, and fundraisers who connect with our Chapters across the nation—are the main force moving us Forward Together As 1. Here, in your words, some of you share what inspires you to move us closer to life-changing breakthroughs to cure T1D and improve lives.



“JDRF helps make our voices louder so that, one day, my son and everybody with T1D can live a normal life and not have to worry about the daily struggles.”

—Janna Gonzalez, JDRF Advocate and mom to 10-year-old Noah


“No other organization has had the impact that JDRF has. They allow my family to be part of the journey to help find a cure.”

—Marjorie Lazarre, Clinical Trial Education Volunteer, and mom to 15-year-old Ava



“It’s an absolute honor to work directly alongside so many incredible folks at JDRF who want to help make the world a bit easier for those who deal with T1D and fight that fight every day.”

—Jamie, aka Jambo, JDRF Game2Give streamer





“I want to assure other AAPI-identifying [Asian American and Pacific Islander] people with T1D that there are others out there with similar backgrounds dealing with the same issues.”

–Kabir Dewan, JDRF Advocates in Action Council member

“JDRF has continuously provided support through events and activities that create a space for me to connect with [others with type 1 diabetes] and be part of an amazing community of those fighting for a cure.”

–Ameera Gee, Greater New York Chapter, Ph.D. Candidate, NYU Grossman School of Medicine



“Through advocacy, fundraisers, and outreach activities, I witness the positive impact of JDRF in our community through raising funds and spirits while accelerating research and innovation.”

–Tim Burkett, Mid Atlantic Chapter, Maryland Community

Curing T1D

Today's most promising cures research involves three key areas:



Cell Therapies, which aim to replace beta cells so that people with T1D can again produce their own insulin.



Disease-Modifying Therapies, which aim to stop, reverse, or delay the immune attack of insulin-producing beta cells in the pancreas.



Screening and Monitoring, which aims to identify and support people at-risk for T1D before disease onset. This can help prevent devastating outcomes at diagnosis. It can also identify people eligible for disease-modifying therapies clinical trials, which can help accelerate the development of these therapies.


Cures: Where We Are Now

First Disease-Modifying Therapy for T1D

Tziel™ (teplizumab-mzwv) was approved by the U.S. Food and Drug Administration (FDA) for use in delaying the onset of T1D in at-risk individuals aged 8+.

This is the first drug to treat the autoimmune process behind T1D, thus altering the course of the disease, and a major watershed moment for the T1D community.





Vertex + ViaCyte = A Turbo Boost for Cell Therapies

Vertex, who previously acquired Semma Therapeutics, also acquired ViaCyte, bringing together the leading companies developing stem cell-based therapies for diabetes.

Vertex is advancing a stem cell-derived islet replacement therapy for T1D. It's in human clinical trials and showing amazing results, with one participant being off insulin entirely.

Vertex also started a trial with a new product using encapsulated stem cell-derived islets as replacement therapy without the need for immunosuppression.

In addition, Vertex is exploring gene-edited stem cell-based therapies—also with the goal of eliminating the need for immunosuppressive drugs.

Engaged and Educated: 250,000+ People about Screening and Monitoring

Since launch, JDRF's screening and monitoring education and awareness program, T1Detect, has educated more than a quarter of a million people about why T1D risk screening matters, how to get screened, and what to do after they are screened.

Screening helps people know if they are at risk of developing T1D. Monitoring helps manage the risk, including avoiding diabetic ketoacidosis (DKA) at diagnosis.

T1Detect aims to increase access to screening by identifying options for all families—including communities that have been underserved by the healthcare system—and provides guidance toward next steps.

[Visit JDRF.org/T1Detect](https://www.jdrf.org/T1Detect)

**Learn About
Screening**




**Get
Screened**



**Follow Up
& Monitoring**





Cures: How We Got Here

Tzield: 35+ Years of JDRF Work

Since the 1980s, JDRF has supported T1D disease-modifying therapy development. These include efforts across the T1D therapy pipeline that specifically led to Tzield: discovery research grants (the first of which was awarded in 1988), clinical trial funding, and advocacy for the regulatory pathway for disease-modifying therapies. In addition, the T1D Fund made a venture capital investment (in 2017) in Provention Bio, the company that developed Tzield.

Cell Therapies: 40 Years of JDRF Work

JDRF's funding of research to develop beta cell transplantation therapies started in the 1980s.

In the early 2000s, JDRF started funding beta cell research advanced by both Vertex and ViaCyte.

Screening and Monitoring: 40+ Years of JDRF Work

JDRF's interests in T1D risk screening go back to the 1980s, when a JDRF-funded physician-scientist discovered that diabetes is associated with the development of islet cell antibodies, a finding instrumental in determining that T1D is an autoimmune disease.

Since then, screening and monitoring have grown in importance as they can help prevent dangerous conditions that require hospitalization at diagnosis, help families prepare for T1D onset, and are critical to accelerating clinical development of additional disease-modifying therapies.

Cures: Looking Forward

T1D Disease-Modifying Therapies Path Will See More Action

Through work to establish a regulatory pathway for disease-modifying therapies, JDRF laid critical groundwork to improve the regulatory prospects for future T1D disease-modifying therapies.

Critically, Tzield's approval has shown pharmaceutical companies that T1D disease-modifying therapies are possible.

Sanofi recently acquired Provention Bio for \$25 per share in cash. This represents a significant financial investment in T1D disease-modifying therapies by one of the world's leading pharmaceutical companies.

This acquisition brings the first T1D disease-modifying therapy available in the U.S. into the portfolio of a leading global pharmaceutical company, representing an endorsement of the potential of these types of therapies and, we hope, the opportunity to bring this life-changing therapy and others in the pipeline to more people faster.

Global Universal Screening and Monitoring via Expanded Awareness, Access

JDRF is partnering with community health centers and safety net hospitals to focus on improving awareness and access for populations underserved by the healthcare system through our T1Detect program.

As more people are screened and find out what the results mean, we will see fewer instances of devastating outcomes at diagnosis and increased participation in clinical trials for T1D disease-modifying therapies.

Cell Therapies Will Allow People to Remove Devices, Walk Away from T1D

Human clinical trials will continue and advance us closer to commercialized cell therapies.

Cell therapies research will continue to investigate how to keep the beta cells alive and healthy through gene editing, encapsulation, and immune modulation.





JDRF T1D Fund

In 2016, a group of JDRF volunteers identified the need to attract more private investment for the development of T1D cure therapies. Their vision resulted in the creation of the T1D Fund, an impact investment fund that has used a venture philanthropic approach to catalyze over \$700 million of private investment in our mission and transformed the fight to cure T1D. The Fund's unique approach to philanthropy relies on offering the global network and knowledge of JDRF and the Helmsley Charitable Trust as a resource for investors. This unparalleled source of expertise, delivered through a professional venture fund, has created a bridge between research and commercial development and has activated the biotech industry to translate research into T1D cure therapies. The FDA approval of Tzield is an example of a program that benefited from early investment and support by the Fund.


As of June 2022, the Fund has invested ~\$81 million in 31 companies and has attracted more than \$634 million of private capital alongside it to be used in T1D programs. In addition, the Fund's investment strategy has resulted in more than \$54 million of returns recycled back for future investment. Funded by over \$100 million of gifts from just over 100 donors and support from JDRF, in six years the T1D Fund has become one of the largest disease-focused venture philanthropy funds in the world and the only one focused on T1D.


T1D Fund Portfolio Companies



Improving Lives

Today's most promising life-improving opportunities focus on two main areas:

 **Glucometabolic Control** aims to improve glucose and other metabolic outcomes and make it easier to manage T1D. These include novel technologies, better insulins, and adjunctive therapies that complement insulin.

 **Complications and Psychosocial** areas aim to delay or prevent long-term eye, heart, and kidney disease and improve mental health and well-being.



Improving Lives: Where We Are Now

Affordable Insulins for Everyone, Regardless of Insurance Status

JDRF and partnering organizations are supporting nonprofit pharmaceutical manufacturer Civica Rx to produce biosimilar insulin that will cost no more than \$30 a vial/\$55 a box of five pens, regardless of insurance status.

One year after the Civica announcement, Lilly, Novo Nordisk, and Sanofi all announced reductions to the prices of their insulins—including the most used insulins, such as Humalog, NovoLog, and Lantus.

Another big win for insulin affordability was the \$35 monthly out-of-pocket co-pay cap for those on Medicare included in the Inflation Reduction Act that JDRF fought hard to secure.



A New Way to Defeat Diabetes Distress

Young adults have the highest levels of diabetes distress and blood sugar levels among all age groups. This is especially the case for young adults within communities that have been underserved by the healthcare system.

JDRF-funded researchers are investigating whether telemedicine-delivered cognitive behavioral therapy (CBT) can reduce diabetes distress and improve blood sugar management for this population.

CBT aims to help people recognize dysfunctional thought and behavioral patterns and replace them with thought and behavioral patterns aimed at improved outcomes.

First Tubeless AP System, Interoperable Algorithm, and Long-Term Implantable CGM

There are now four approved artificial pancreas (AP) systems, including the first tubeless AP system, the Insulet Omnipod® 5.

In addition, the FDA approved the Tidepool Loop—an algorithm that will allow for interoperability of commercial continuous glucose monitors (CGMs) and insulin pumps. This will provide flexibility for AP users and their healthcare teams to choose the compatible components that work best for them.

All four approved AP systems and Tidepool Loop were developed at some point with JDRF funding.

People with T1D can choose from several approved CGMs—including Eversense® E3, the first long-term implantable CGM featuring technology that can extend its use for up to 6 months!

Advanced insulin pumps and user-friendly apps help facilitate more timely tracking and management of blood-glucose levels.

These technologies are leading to better health for people with T1D by reducing dangerous highs and lows, improving time-in-range, allowing for healthy pregnancies, and even leading to better sleep.

Thanks to JDRF, all major healthcare plans and Medicare cover these technologies.



Photos courtesy Insulet maker Omnipod 5 Podders T’Kara, Kate, Gregg, and Sydney.

Could “Miracle” T2D Medications Work for T1D?

SGLT inhibitors (such as Jardiance®) and GLP-1 medications (such as Ozempic®) seem to be the modern “miracle” drugs for people with type 2 diabetes (T2D). They can lower blood-sugar levels and lead to weight loss. Crucially, these medicines can also lower the risk of major cardiovascular disease events and or major kidney disease events.

JDRF is funding numerous studies to investigate whether these drugs can also lower blood-sugar levels for people with T1D and protect them from major heart or kidney disease events without increasing the risk of dangerous highs or lows in blood sugar.

Improving Lives: How We Got Here

Affordable Insulin: Nearly 10 Years of JDRF Work

As insulin prices have dramatically risen during the past decade, JDRF has worked with all stakeholders—including insulin manufacturers, health coverage providers, pharmacy benefit managers (PBMs), and employers—to make insulin more affordable.

JDRF has consistently supported the development of and access to new insulins, including biosimilar and interchangeable insulins, the first of which—Semglee®—was approved in 2021.

T1D Management Technologies: Nearly 50 Years of JDRF Work

Since the early 1970s, JDRF has successfully led the charge to advance the standard of care for T1D management from finger pricks, test strips, blood glucose meters, and daily injections to insulin pumps, CGMs, and AP systems.

This includes efforts in research and development, regulatory approval, healthcare coverage, and widespread adoption of insulin pumps, CGMs, and AP systems.

Psychosocial Health: 34 Years of JDRF Work

JDRF began funding research in T1D and psychosocial health nearly three decades before the 2018 launch of the JDRF Psychosocial Health Program.

In the past five years alone, JDRF has awarded 15 grants to support psychosocial research—exploring topics that range from T1D and eating disorders, reducing disparities in at-risk youth, diabetes distress, and anxiety.

Through JDRF's National Diabetes Psychology Fellowship Program, 24 psychologists have developed expertise in addressing the unique needs of people impacted by T1D.

Kidney and Heart Disease Therapies: 50+ Years of JDRF Work

JDRF has funded complications research since we were established, awarding one-third of our grants to find the underlying causes of and treatments for heart, kidney, eye, and other T1D-related diseases.

GLP-1 medications are rooted in JDRF-funded research. In the 1980s, JDRF-funded researcher Pauline Kay Lund, Ph.D., was the first to clone the hormone glucagon and discover two new hormones, one of which was GLP-1.



Improving Lives: Looking Forward



Affordable Insulins Available at Your Pharmacy Counter

Through Civica Rx, starting in 2024, biosimilars to three of the most widely used insulins in the United States—glargine (Lantus), lispro (Humalog) and aspart (NovoLog)—will be available at your pharmacy counter and at the same, reasonable price, regardless of your insurance status.



Smarter, Smaller, Better T1D Management Technologies

Until the day that no one needs them, AP systems, CGMs, and insulin pumps will continuously improve in functionality, user-friendliness, size, and interoperability.

JDRF will continue to ensure these devices are covered by all major healthcare plans.



An Improved Standard of Care for T1D and Psychosocial Health

If the CBT study shows that teletherapy reduces diabetes distress and improves health outcomes in young adults with T1D, JDRF would establish a new model of T1D care that can be easily integrated into clinical practice.



A More Streamlined Path to Healthier Hearts and Kidneys

If the clinical trial results for SGLT inhibitors, GLP-1 activators and other medications are positive for people with T1D, translation to clinical use could be streamlined, as these are already FDA approved for the treatment of T2D and non-diabetes.

The Special Diabetes Program

JDRF Advocacy works to ensure that the federal government continues to invest in T1D research. The primary way this happens is through the Special Diabetes Program (SDP), which currently **provides \$150 million annually to T1D research through the National Institutes of Health (NIH)**. This program has dedicated \$3.4 billion to T1D research since its inception in 1998. The SDP touches numerous T1D research areas, including environmental triggers, disease-modifying therapies, glucose control, and complications. NIH and JDRF scientists work together closely to ensure that funding for the SDP and JDRF builds toward aligned and collaborative goals. **JDRF is the chief advocate for the SDP and is advocating for SDP's renewal in 2023 and beyond.**



The T1D Index: A First-of-Its-Kind Life-Saving Initiative

The Type 1 Diabetes Index (T1D Index), a first-of-its-kind data simulation tool launched by JDRF and some of our leading partners, provides the most accurate, comprehensive picture of T1D in every nation around the world. Data from the Index tells us the true global scope and impact of T1D, which has never before been measured in this way or at this scale. The Index measures and maps how many people live with T1D, the healthy years of life taken from people living with T1D, and the number of people who would still be alive today if they hadn't died prematurely from T1D complications.



It's Time to Change the Story

Data from the Index will empower JDRF and our partners to pinpoint where the biggest issues are and, using local stakeholders such as community-based organizations, drive change through four key areas of intervention.



Timely Diagnosis If we could promptly diagnose everyone affected by T1D, 668,000 more people could be alive in 2040.



Insulin and Strips If everyone globally had access to insulin, test strips, and good self-management tools, 1.98 million more people could be alive in 2040.



Pumps and CGMs If everyone globally had access to technology that automates glucose monitoring and insulin delivery, 673,000 more people could be alive in 2040.




Prevention and Cures By researching and investing in emerging treatments and cures, we could restore full length and quality of life to everyone who develops T1D.

Engaging with the Full Spectrum of the T1D Community

To advance toward our vision of a world without T1D, we must engage with the full spectrum of the T1D community.

Our organizational commitment to Diversity, Equity, Inclusion, and Belonging (DEIB) underpins our Health Equity Initiatives. These efforts—which span across our mission pillars of research, advocacy, and community engagement—help accelerate us as quickly as possible toward cures and life-improving therapies and technologies for all impacted by T1D.



By The Numbers: Community Engagement

Our community members and Chapters across the country remained dedicated to increasing T1D awareness, providing support for people living with T1D—including newly diagnosed families—and raising funds to advance our mission.



One Walk

44,400+ Walkers
8,700+ Teams



Ride

2,000+ Riders
29 Chapter Teams



Gala

23,500+ Guests
53 Events



Golf

3,490+ Golfers
24 Events



TEAM JDRF

980+ Participants
99 Teams



Your Way

1,300+ Participants
696 Events



Bag of Hope® and No Limits™ Care Kits

21,300+ Distributed



TypeOneNation Summits

8,100+ Registrants
40+ Events (in-person & virtual)



TypeOneNation Summits Spanish

12,800+ Registrants
11+ Events (in-person & virtual)



Game2Give®

53,700+ T1D Game
Bundles Sold
200+ Streaming
Fundraiser Events


By The Numbers: Our Impact

JDRF accelerates life-changing breakthroughs by raising funds and allocating them to T1D research and therapy development, as well as by leveraging our expertise and leadership to bring in additional funding and supporters from around the world.

In FY22, the JDRF T1D Fund catalyzed \$158.2 million in private venture capital investment in novel companies developing innovative T1D therapies. This is included in the \$171M of Industry Partnerships and Investments

\$473M

Total research support



JDRF drew \$376M in additional funding and investments for T1D research

Our Impact: Looking Forward

This leverage will continue to be a key part of JDRF's strategy to accelerate as many cures and life-improving therapies as quickly as possible. As JDRF expands its role as the leading global T1D organization, our leverage will increase and will empower us to more quickly grow global support of and investment in T1D research. It will also continue to directly engage more sources of capital in the investment and pharmaceutical sectors, which are essential to achieving our goal of curing T1D.



By The Numbers: T1D Therapy Research and Development

JDRF researchers work with the world’s leading scientists and institutions to advance the most promising T1D innovations. **Last year, we funded more research in more countries around the world and saw a nearly 170% increase in the number of new research grants funded, as well as a 120% increase in funding for new clinical trials.**



21+

Countries with JDRF Supported Research (includes U.S.)



400+

Active Projects



20

Early-Career Scientists Received New and Supplemental Funding



158

New Research Grants



60

Clinical Trials



\$11M

To New Clinical Trials


More Than \$1 Billion to Cures and Improving Lives

During the past five fiscal years, through JDRF’s research grants and JDRF T1D Fund investments (those that we have made, as well as private, alongside investments), **more than \$1 billion** has been directed to cure T1D and improve lives—with most of it (approximately 80 percent) focused on cures.

JDRF Grants and T1D Fund Investments: FY18 through FY22

Improving Lives

20%



\$1B+
Total Grants & T1D Fund Investments

Curing T1D
80%

By The Numbers: FY22 Revenue

JDRF has four main revenue streams: Events (Walk, Ride, Gala, etc.); Contributions (gifts, etc.); Investment Gains/Losses (JDRF T1D Fund and other investments), and International Affiliates/Other (funding raised by our five International Affiliates, other sources).


For FY22, we saw increases in our Events, Contributions, and International Affiliates/Other revenue streams. We also saw a loss in our Investment Gains/Losses revenue stream.

\$101M

Events
(galas, walks,
rides, etc.)

\$95M

Contributions



\$196M
In Revenue

(\$32M)

Investment Gains/
Losses

\$32M

International
Affiliates/Other

Why Did We See a Loss in Investment Gains/Losses?

Calendar year 2022 was a bear for the financial markets. In fact, 2022 was the worst year for financial markets since the financial crisis of 2008. As such, in FY22 JDRF saw a loss of \$32 million in our Investment Gains/Losses revenue stream. Peer nonprofit organizations across the country have experienced similar losses. JDRF's financial health remains strong, and the challenging economic environment did not impact our research grant funding. So too, our T1D Fund's portfolio remains strong as we look forward beyond 2022.



Revenue: Looking Forward

Financial markets by their very nature ebb and flow, and we are poised for a rebound in that revenue stream when the markets rebound.

To move as many cures and advanced therapies forward as quickly possible, we must raise more funds. Our fundraising strategy seeks to maximize revenue growth by tailoring our fundraising programs to our communities—empowering us to raise more funds, more efficiently.




By The Numbers: FY22 Mission Spend

As we returned to in-person fundraising events, we saw more revenue we could deploy to mission. In FY22, JDRF spent 50% more on advancing our mission than we did in FY21. **This includes a 69% spending increase over FY21 for research funding and investments (grants, support, advocacy, and new T1D Fund investment), and a 16% spending increase over FY21 in public education/community engagement.**

\$97M

JDRF Research Funding
and Investments

(grants, support, advocacy,
new T1D Fund investments)



Mission Spend: Looking Forward

The global burden of T1D is growing. JDRF has ambitious goals to move more T1D cures and advanced therapies forward, as quickly as possible.

To accomplish this, we need to raise more funds, and we need to engage more people through our public education (community engagement) programs, our efforts to activate volunteers, and our efforts to strengthen our staff-volunteer partnerships.

Engaging more people helps more individuals with T1D live healthier lives, expands our community, amplifies and unifies our voice, and helps further accelerate the path to cures and advanced therapies.



29 Chapters

Supporting more than

1 million people

JDRF Chapters engage and support people with T1D and their loved ones in every major area of the United States. Our Chapters empower families through community connections, educational resources, events, and opportunities to volunteer.

JDRF's global footprint includes five international affiliates and research in 21 countries, including research conducted at JDRF Centers of Excellence, located in the United States, Canada, and Australia.




Australia



Canada



Israel



Netherlands



United Kingdom

Industry Partners, Governments, Organizations

Our advocacy, leadership, and expertise attracts additional funding for cures and improving lives from:



The U.S. government and international governments



Other nonprofit organizations and foundations



Industry partners—including pharmaceutical and technology companies

Together, we are a strong network focused on advancing innovation.

Corporate Partners

Through our robust community engagement and educational programs, JDRF empowers members of the T1D community to live better lives.

Diamond Partners

Contributing more than \$2,500,000 annually



Platinum Partners Contributing between \$1,000,000 & \$2,499,999 annually



Abbott



Medtronic



Gold Partners Contributing between \$500,000 & \$999,999 annually

DEXCOM

HyVee



proventionbio

Wawa

Silver Partners

Contributing between \$250,000 & \$499,999 annually

Harris Teeter

Nordstrom

Xeris Pharmaceuticals

Tops Friendly Markets

Bronze Partners

Contributing between \$100,000 & \$249,999 annually

AmazonSmile
Foundation

AmerisourceBergen

Ascensia Diabetes Care

Becton, Dickinson
and Company

Charitable Adult Rides
& Services (CARS)

Dompé US

Floyd's 99 Barbershop

Genentech
Insulet

Kemper
Land O' Frost

MannKind

Tandem Diabetes Care

Transcarent
Veradigm

IBOD Welcomes New Leaders



In April 2022, JDRF announced two long-term volunteers as our International Board of Directors (IBOD) Chair and Vice Chair, starting July 1, 2022.

Grant Beard, Executive Operating Partner, LP, and Co-investor at Blue Point Capital Partners, was named JDRF IBOD Chair, succeeding Joseph (Joe) P. Lacher. Michelle Griffin, a management consultant with more than 25 years of experience,

was named JDRF IBOD Vice Chair, succeeding Lisa Fishbone Wallack.

Grant and his wife Susan have been volunteer leaders since their daughter Emily's T1D diagnosis in 2006 at age 14. They were recognized for their support of T1D research and research-related education with the 2016 Jane Jospey Cobb Promise Award.

Michelle's son Cameron was diagnosed with T1D in 2007 at age nine and she and her husband, Tom Parker, have been actively involved with JDRF since. In 2017, Michelle received the Jim Tyree Chairman's Choice Award for her noteworthy volunteer contributions to JDRF.

During their two-year term, Joe and Lisa led JDRF through the COVID-19 pandemic, one of the most challenging times in JDRF's history. JDRF thanks Joe and Lisa for their amazing leadership and unstoppable commitment to the diabetes community. We look forward to Grant and Michelle building on their success.

Remembering T1D Champion, Steve Davis



Steve Davis was a leader in the restaurant and consumer packaged goods industries, but to JDRF, he was a beloved member of the JDRF family and our International Board of Directors.

Sadly, Steve passed away of sudden cardiac arrest on July 10, 2022.

We are forever grateful for Steve's many years of service to JDRF, as well as the time, talent, and support he generously dedicated to changing the world for people living with T1D.

Steve and his wife, Lynnda, got involved with JDRF's Central Ohio Chapter when their daughter was diagnosed with T1D in 2009.

Steve was a true T1D champion and changemaker. The impact of his philanthropic efforts will benefit the T1D community for years to come and we are grateful for the role he played in bringing us closer to curing T1D.

JDRF FY22 International Board of Directors

Joseph P. Lacher, Jr.

Chair

Lisa F. Wallack

Vice Chair

Michael Alter

Chair, Funding Committee

Grant Beard

Chair, Audit and Risk Committee

Elizabeth Caswell

Vice Chair, Research Committee

Steven Davis

Chair, Nominating and Governance Committee

Claudia Graham, Ph.D., MPH

Paul Heath

Chair, Advocacy and Impact Committee

Karen Jordan

Chair, Research Committee

Jeff Plumer

Chair, Talent and Compensation Committee

Jennifer Schneider, M.D.

Christopher H. Turner

Chair, Finance and Investment Committee

Matt Varey

Drayton Virkler

Karey L. Witty

JDRF T1D Fund FY22 Board of Directors

Sean Doherty

Chair

Gina Agiostratidou

The Leona M. and Harry B. Helmsley Charitable Trust

Grant Beard

Timothy Clark

Jay Eastman

Karen Jordan

Aaron J. Kowalski, Ph.D.

CEO, JDRF

Ellen Leake



JDRF FY22 Global Mission Board

The Global Mission Board is a group of national volunteer leaders who accelerate JDRF's mission progress through special initiatives.

Kim Roosevelt

Chair

Jennifer Bennett

Chair Elect

Jeff Adams

Randy Anderson, Ph.D.

Brandon Arbiter

Carmen Ashley

Cathy Baier

Timothy Clark

Toni Clark

Matthew Cohn

Jennie Costner

Marvin Daitch

Nanette DeTurk

Pam Edmonds

Cynthia Ford

Michelle Griffin

Ardy Johnson

Ian Joyce

Mark Kacher

Marshall Lang

Mike Lee

James Lurie, Esq.

Mike Norona

Dayton Ogden

Carol Oxenreiter

Margery Perry

Derek Rapp

Lisa Reed

Brad Schur

Lorne Schiff

Michael Soper

Jerry Wisler

FY22 Financial Statement Summary

Total Public Support and Revenue for the year ended June 30, 2022 were as follows (in \$thousands):

Public Support

Contributions	95,406
Events revenue, net	100,545
Contributions from international affiliates	<u>8,621</u>

Total Public Support **204,572**

Investment loss, net **(31,507)**

Other income **22,664**

Total Public Support and Revenue **195,729**

Allocation of Expenses

Mission program services:

Research and advocacy, net ¹	84,459
Public education and outreach	<u>36,810</u>

Total mission program services **121,269**

Mission support services:

Management and general	11,681
Fundraising	<u>28,423</u>

Total mission support services **40,104**

Total mission program services and support services **161,373**

¹Does not include T1D Fund investments of \$12.96 million; total research expenditures in FY22 were \$97.42 million

Statement of Financial Position

June 30, 2022 (in \$thousands)

Assets

Cash and cash equivalents	38,318
Investments:	
Operating and restricted investments	132,349
Long-term investments	81,120
Programmatic investments	50,551
Contributions receivable, net	58,975
Programmatic notes receivable, net	2,219
Prepaid expenses and other	15,358
Fixed assets, net	10,571
Total assets	<u>389,461</u>

Liabilities and Net Assets

Liabilities:

Accounts payable and accrued expenses	17,575
Research grants payable	69,410
Deferred revenue	5,150
Liabilities related to split-interest agreements	2,416
Total liabilities	<u>94,551</u>

Net assets:

Without donor restrictions	229,546
With donor restrictions	65,364
Total net assets	<u>294,910</u>
Total liabilities and net assets	<u>389,461</u>

Every gift takes us one step closer to finding cures for T1D. Find out how you can support JDRF and make a difference in the lives of people with T1D by visiting **jdrf.org**.

jdrf.org

Follow us:

 facebook.com/myjdrf

 [@JDRF](https://twitter.com/JDRF)

 [@JDRFHQ](https://instagram.com/JDRFHQ)

 [@JDRFHQ](https://tiktok.com/@JDRFHQ)

 [@JDRF](https://youtube.com/JDRF)

JDRF IMPROVING
LIVES.
CURING
TYPE 1
DIABETES.